肝癌免疫治疗的研究进展

Progress in immunotherapy for hepatocellular carcinoma

摘要:

肝细胞肝癌是全球发病率和死亡率最高的恶性肿瘤之一，发病率和死亡率呈逐年上升趋势。我国是肝癌大国，每年肝癌的死亡病例数位居全球第一。免疫治疗是继手术、化疗和放疗之后新兴的癌症治疗手段，其通过解除肿瘤微环境对免疫细胞的抑制作用并激活机体免疫功能，实现控制和杀伤肿瘤细胞。常用的免疫治疗的方法有免疫检查点治疗、过继免疫治疗和肿瘤疫苗治疗等。与传统治疗手段相比，免疫治疗因具有增强机体免疫功能、延缓肿瘤进展、延长患者生存时间等优点，逐渐成为基础和临床研究的热点。文中就免疫治疗在肝癌领域的研究进展作一综述。

Abstract:

Hepatocellular carcinoma (HCC) is one of the malignant tumors with the highest morbidity and mortality in the world. The morbidity and mortality of HCC are increasing every year. Liver cancer is a serious threat to public health in China and the death rate of patients with liver cancer in China is the highest in the world. Beyond surgery, chemotherapy and radiotherapy, immunotherapy is an emerging treatment for cancer, which could control and kill tumor cells by relieving the inhibitory status of immune cells in the tumor microenvironment and activating the immune function of the body. Immune checkpoint inhibitors, adoptive immunotherapy and tumor vaccine are the major treatments of immunotherapy. Compared with traditional therapy methods, immunotherapy could enhance immune function, delay tumor progression, prolong the survival time of patients, and becomes a hotspot in the basic and clinical cancer research. This article reviews the research progress of immunotherapy for liver cancer.